Literature DB >> 7887379

Symptom-limited arm exercise increases detection of ischemia during dipyridamole tomographic thallium stress testing in patients with coronary artery disease.

L Stein1, R Burt, B Oppenheim, D Schauwecker, N Fineberg.   

Abstract

Exercise combined with dipyridamole during thallium stress testing in patients with coronary artery disease (CAD) increases the frequency of angina and ischemic ST changes in the electrocardiogram. Evidence for an increase in thallium abnormalities has been inconclusive. We prospectively examined 54 consecutive patients who underwent coronary angiography and tomographic thallium with dipyridamole (0.57 mg/kg) alone and combined with symptom-limited dynamic arm exercise. Most patients presented with a history of chest pain and 49 had angiographic evidence of significant coronary stenosis (50% diameter narrowing). Thallium abnormalities were scored blindly by consensus. The number of abnormal segments (total and ischemic) and indexes of left ventricular dysfunction, such as increased lung uptake or ischemic dilation, were compared in the 49 patients with CAD. During arm exercise more patients had evidence of ischemia (39 vs 30; p < 0.001), and the number of ischemic segments increased significantly from 1.3 +/- 1.5 to 2.5 +/- 2.2 (p < 0.001). There was also a significant increase in the indexes of left ventricular dysfunction, ischemic dilation (10 vs 4 patients; p < 0.03) and increased lung uptake (16 vs 5 patients; p < 0.001). Patients who exercised had increased thallium evidence of extent and severity of ischemia and more frequent indexes of left ventricular dysfunction. Thus, symptom-limited arm exercise improves detection of extent and severity of ischemia in patients with CAD undergoing dipyridamole thallium stress testing.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7887379     DOI: 10.1016/s0002-9149(99)80618-3

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

1.  Pharmacologic stress testing: understanding the options.

Authors:  M P White
Journal:  J Nucl Cardiol       Date:  1999 Nov-Dec       Impact factor: 5.952

2.  Safety and feasibility of atropine added to submaximal exercise stress testing with Tl-201 SPECT for the diagnosis of myocardial ischemia.

Authors:  Sanjay K Prasad; Dudley J Pennell
Journal:  J Nucl Cardiol       Date:  2002 Nov-Dec       Impact factor: 5.952

3.  Symptom-limited exercise combined with dipyridamole stress: prognostic value in assessment of known or suspected coronary artery disease by use of gated SPECT imaging.

Authors:  Alan W Ahlberg; Sarkis B Baghdasarian; Haris Athar; Jeffrey P Thompsen; Deborah M Katten; Gavin L Noble; Igor Mamkin; Anuj R Shah; Ivette A Leka; Gary V Heller
Journal:  J Nucl Cardiol       Date:  2008 Jan-Feb       Impact factor: 5.952

4.  Exercise supplementation to dipyridamole prevents hypotension, improves electrocardiogram sensitivity, and increases heart-to-liver activity ratio on Tc-99m sestamibi imaging.

Authors:  J V Vitola; J C Brambatti; F Caligaris; C R Lesse; P R Nogueira; A I Joaquim; M Loyo; F V Salis; E V Paiva; W A Chalela; J C Meneghetti
Journal:  J Nucl Cardiol       Date:  2001 Nov-Dec       Impact factor: 5.952

5.  Arm exercise stress perfusion imaging predicts clinical outcome.

Authors:  Albert K Chan; Nasreen A Ilias-Khan; Hong Xian; Cindi Inman; Wade H Martin
Journal:  J Appl Physiol (1985)       Date:  2011-08-18

Review 6.  Pharmacologic radionuclide myocardial perfusion imaging.

Authors:  Sachin M Navare; Athanasios Kapetanopoulos; Gary V Heller
Journal:  Curr Cardiol Rep       Date:  2003-01       Impact factor: 2.931

7.  Short-duration, submaximal intensity exercise stress combined with adenosine triphosphate decreases artifacts in myocardial perfusion single-photon emission computed tomography.

Authors:  Yukinori Shinoda; Koichi Tachibana; Tomoko Minamisaka; Hidetada Fukuoka; Hirooki Inui; Keisuke Ueno; Soki Inoue; Kentaro Mine; Kumpei Ueda; Shiro Hoshida
Journal:  BMC Cardiovasc Disord       Date:  2020-10-07       Impact factor: 2.298

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.